BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 27683821)

  • 21. Dynamic Changes in Ex Vivo T-Cell Function After Viral Clearance in Chronic HCV Infection.
    Han JW; Sung PS; Kim KH; Hong SH; Shin EC; Jun Song M; Park SH
    J Infect Dis; 2019 Sep; 220(8):1290-1301. PubMed ID: 31152667
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Autoimmune liver serology before and after successful treatment of chronic hepatitis C by direct acting antiviral agents.
    Terziroli Beretta-Piccoli B; Di Bartolomeo C; Deleonardi G; Grondona AG; Silvestri T; Tesei C; Melidona L; Cerny A; Mertens J; Semmo N; Semela D; Moradpour D; Mieli-Vergani G; Vergani D; Muratori L;
    J Autoimmun; 2019 Aug; 102():89-95. PubMed ID: 31047768
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sustained Virologic Response at 24 Weeks after the End of Treatment Is a Better Predictor for Treatment Outcome in Real-World HCV-Infected Patients Treated by HCV NS3/4A Protease Inhibitors with Peginterferon plus Ribavirin.
    Kanda T; Nakamoto S; Sasaki R; Nakamura M; Yasui S; Haga Y; Ogasawara S; Tawada A; Arai M; Mikami S; Imazeki F; Yokosuka O
    Int J Med Sci; 2016; 13(4):310-5. PubMed ID: 27076789
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study.
    Molina JM; Orkin C; Iser DM; Zamora FX; Nelson M; Stephan C; Massetto B; Gaggar A; Ni L; Svarovskaia E; Brainard D; Subramanian GM; McHutchison JG; Puoti M; Rockstroh JK;
    Lancet; 2015 Mar; 385(9973):1098-106. PubMed ID: 25659285
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lack of full CD8 functional restoration after antiviral treatment for acute and chronic hepatitis C virus infection.
    Missale G; Pilli M; Zerbini A; Penna A; Ravanetti L; Barili V; Orlandini A; Molinari A; Fasano M; Santantonio T; Ferrari C
    Gut; 2012 Jul; 61(7):1076-84. PubMed ID: 22337949
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Persistent gamma delta T-cell dysfunction in chronic HCV infection despite direct-acting antiviral therapy induced cure.
    Ghosh A; Mondal RK; Romani S; Bagchi S; Cairo C; Pauza CD; Kottilil S; Poonia B
    J Viral Hepat; 2019 Sep; 26(9):1105-1116. PubMed ID: 31074195
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Human γδ T Cell Receptor Repertoires in Peripheral Blood Remain Stable Despite Clearance of Persistent Hepatitis C Virus Infection by Direct-Acting Antiviral Drug Therapy.
    Ravens S; Hengst J; Schlapphoff V; Deterding K; Dhingra A; Schultze-Florey C; Koenecke C; Cornberg M; Wedemeyer H; Prinz I
    Front Immunol; 2018; 9():510. PubMed ID: 29616028
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons.
    Chung RT; Andersen J; Volberding P; Robbins GK; Liu T; Sherman KE; Peters MG; Koziel MJ; Bhan AK; Alston B; Colquhoun D; Nevin T; Harb G; van der Horst C;
    N Engl J Med; 2004 Jul; 351(5):451-9. PubMed ID: 15282352
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents.
    Conteduca V; Sansonno D; Russi S; Pavone F; Dammacco F
    J Infect; 2014 Jan; 68(1):1-20. PubMed ID: 24012819
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Liver fibrosis progression despite HCV cure with antiviral therapy in HIV-HCV-coinfected patients.
    Labarga P; Fernandez-Montero JV; de Mendoza C; Barreiro P; Pinilla J; Soriano V
    Antivir Ther; 2015; 20(3):329-34. PubMed ID: 25372299
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Early virological response may predict treatment response in sofosbuvir-based combination therapy of chronic hepatitis c in a multi-center "real-life" cohort.
    Steinebrunner N; Sprinzl MF; Zimmermann T; Wörns MA; Zimmerer T; Galle PR; Stremmel W; Eisenbach C; Stein K; Antoni C; Schattenberg JM; Pathil A
    BMC Gastroenterol; 2015 Aug; 15():97. PubMed ID: 26239732
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Immunology of HCV infection: the causes of impaired cellular immune response and the effect of antiviral treatment].
    Pár G; Berki T; Pálinkás L; Balogh P; Szereday L; Halász M; Szekeres-Barthó J; Miseta A; Hegedus G; Mózsik G; Hunyady B; Pár A
    Orv Hetil; 2006 Apr; 147(13):591-600. PubMed ID: 16623441
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical implications of chemokines in acute and chronic hepatitis C virus infection.
    Kang W; Shin EC
    Yonsei Med J; 2011 Nov; 52(6):871-8. PubMed ID: 22028149
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Longitudinal analysis of peripheral and intrahepatic NK cells in chronic HCV patients during antiviral therapy.
    Spaan M; van Oord GW; Janssen HL; de Knegt RJ; Boonstra A
    Antiviral Res; 2015 Nov; 123():86-92. PubMed ID: 26363298
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hepatitis C virus - associated B cell non-Hodgkin's lymphoma.
    Mihăilă RG
    World J Gastroenterol; 2016 Jul; 22(27):6214-23. PubMed ID: 27468211
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis.
    Hézode C; Fontaine H; Dorival C; Zoulim F; Larrey D; Canva V; De Ledinghen V; Poynard T; Samuel D; Bourliere M; Alric L; Raabe JJ; Zarski JP; Marcellin P; Riachi G; Bernard PH; Loustaud-Ratti V; Chazouilleres O; Abergel A; Guyader D; Metivier S; Tran A; Di Martino V; Causse X; Dao T; Lucidarme D; Portal I; Cacoub P; Gournay J; Grando-Lemaire V; Hillon P; Attali P; Fontanges T; Rosa I; Petrov-Sanchez V; Barthe Y; Pawlotsky JM; Pol S; Carrat F; Bronowicki JP;
    Gastroenterology; 2014 Jul; 147(1):132-142.e4. PubMed ID: 24704719
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sofosbuvir and ribavirin in HCV genotypes 2 and 3.
    Zeuzem S; Dusheiko GM; Salupere R; Mangia A; Flisiak R; Hyland RH; Illeperuma A; Svarovskaia E; Brainard DM; Symonds WT; Subramanian GM; McHutchison JG; Weiland O; Reesink HW; Ferenci P; Hézode C; Esteban R;
    N Engl J Med; 2014 May; 370(21):1993-2001. PubMed ID: 24795201
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection.
    Gane EJ; Hyland RH; An D; Svarovskaia E; Pang PS; Brainard D; Stedman CA
    Gastroenterology; 2015 Nov; 149(6):1454-1461.e1. PubMed ID: 26261007
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The combination of simeprevir and sofosbuvir is more effective than that of peginterferon, ribavirin, and sofosbuvir for patients with hepatitis C-related Child's class A cirrhosis.
    Pearlman BL; Ehleben C; Perrys M
    Gastroenterology; 2015 Apr; 148(4):762-70.e2; quiz e11-2. PubMed ID: 25557952
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New direct-acting antivirals' combination for the treatment of chronic hepatitis C.
    Asselah T; Marcellin P
    Liver Int; 2011 Jan; 31 Suppl 1():68-77. PubMed ID: 21205141
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.